🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseLiver biopsy changes on semaglutide — need advice

Liver biopsy changes on semaglutide — need advice

mike.trainer_LA Mon, Jun 23, 2025 at 2:09 AM 14 replies 1,362 viewsPage 1 of 3
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Jun 23, 2025 at 2:09 AM#1

Writing this once so I can stop repeating it across threads. It is about semaglutide, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

The condition it depends on

"tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

The practical version

Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

What I am not sure about

What would genuinely help is knowing what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss. Happy to be told the question itself is wrong.

— mike.trainer_LA · corrections welcome and will be edited into this post with credit
33 3Dr.AddMedPHL, newstart_MO, mia_MS2 and 30 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Jun 23, 2025 at 2:39 AM#2
mike.trainer_LA said:
The dose-response is real but shallow at the top.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

32 2ricardo_MIA, BrianDallas92, labquiet_amy and 29 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Jun 23, 2025 at 3:09 AM#3
mike.trainer_LA said:
The dose-response is real but shallow at the top.

I read this differently from mike.trainer_LA, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Happy to go further on any of that.

Last edited: Jun 23, 2025 at 7:09 AM
31 1Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 28 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Jun 23, 2025 at 3:39 AM#4

Short answer first, then the reasoning. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

30 0julia.endo, JessicaM_2024, TomFromTexas and 27 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Jun 23, 2025 at 6:22 AM#5
CarlaRPh_TPA said:
All true, with one condition: that curve is for people who reached the dose on schedule.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

29 24TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 26 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register